ASP 5094

Drug Profile

ASP 5094

Alternative Names: ASP5094

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Integrin alpha9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 07 Sep 2017 Astellas Pharma completes a phase I trial in Rheumatoid arthritis (Adjunctive treatment) in USA and Poland (IV) (NCT02698657)
  • 28 Aug 2017 Astellas Pharma plans a phase II trial for Rheumatoid arthritis (Adjunctive treatment) (NCT03257852)
  • 31 Jul 2017 Phase-II clinical trials in Rheumatoid arthritis (Adjunctive therapy) in Japan (IV) (Astellas pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top